Roble, Belko & Company, Inc Mirum Pharmaceuticals, Inc. Transaction History
Roble, Belko & Company, Inc
- $629 Million
- Q4 2024
A detailed history of Roble, Belko & Company, Inc transactions in Mirum Pharmaceuticals, Inc. stock. As of the latest transaction made, Roble, Belko & Company, Inc holds 19 shares of MIRM stock, worth $903. This represents 0.0% of its overall portfolio holdings.
Number of Shares
19Holding current value
$903% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MIRM
# of Institutions
211Shares Held
53.8MCall Options Held
2.6KPut Options Held
99.7K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$313 Million16.29% of portfolio
-
Janus Henderson Group PLC London, X04.58MShares$218 Million0.1% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$154 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.8MShares$133 Million4.33% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.61MShares$124 Million2.07% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.75B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...